Next Generation Sequencers

Next Generation Sequencers

Global Next Generation Sequencers Market to Reach US$43.3 Billion by 2030

The global market for Next Generation Sequencers estimated at US$14.1 Billion in the year 2023, is expected to reach US$43.3 Billion by 2030, growing at a CAGR of 17.4% over the analysis period 2023-2030. Next Generation Sequencers Consumables, one of the segments analyzed in the report, is expected to record a 17.2% CAGR and reach US$26.6 Billion by the end of the analysis period. Growth in the Next Generation Sequencers Platforms segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 22.9% CAGR

The Next Generation Sequencers market in the U.S. is estimated at US$3.8 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.0 Billion by the year 2030 trailing a CAGR of 22.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 15.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global Next Generation Sequencers Market - Key Trends and Drivers Summarized

Next-Generation Sequencing (NGS) technologies, initiated in 2005, have revolutionized the field of genetics by allowing for the simultaneous sequencing of multiple DNA strands, a significant advancement over the traditional Sanger sequencing. This technology, originally dubbed "massively-parallel sequencing," offers unprecedented speed and reduced costs, making extensive genomic studies more accessible. While Sanger sequencing is still utilized for smaller projects or to validate NGS results due to its high accuracy, NGS excels in efficiency and scalability, analyzing hundreds to thousands of genes across various samples in a single run. NGS detects a wide range of genomic features from single nucleotide variants to complex structural variations and RNA fusions, facilitating extensive genetic analyses that were previously unfeasible.

NGS stands out not just for its volume handling but also for its lower sample requirements, higher accuracy, and the ability to detect rare genetic variants. These attributes make it an essential tool in diverse fields such as medicine, agriculture, and environmental science, advancing genomic research, clinical diagnostics, and forensic investigations. The NGS process is intricate, beginning with the construction of a sequencing library where DNA or cDNA samples are fragmented and linked to unique molecular adaptors for easy identification. This is followed by clonal amplification of the DNA fragments on a solid surface to enhance signal detection during sequencing, using technologies that employ a `sequencing by synthesis` approach. Instruments involved in this process detect each nucleotide addition either through optical signals or, as in Ion Torrent technology, electrical signals produced by hydrogen ions released during DNA synthesis. The data analysis phase is complex, involving multiple stages of interpretation to transform raw sequencing data into valuable genetic insights.

The broad application of NGS across various sectors underscores its advantages of high throughput, speed, and cost-efficiency. In clinical research, NGS aids in identifying genetic variations associated with diseases, paving the way for targeted therapies and playing a vital role in reproductive health through genetic anomaly screenings. In agriculture, it accelerates crop improvement by facilitating plant genetic studies, leading to the cultivation of more robust crop varieties. NGS has been particularly crucial during global health emergencies, such as the COVID-19 pandemic, by enabling rapid viral genomic sequencing, which assists in tracking mutations and vaccine development. The future of NGS looks promising with ongoing advancements expected to enhance personalized medicine, agricultural development, and more, fueled by growth drivers such as integration with cloud computing, advancements in bioinformatics, rising consumer interest in personalized medicine, expanding academic and clinical research, evolving regulatory and ethical frameworks, strategic collaborations, and increased investments in emerging markets.

Select Competitors (Total 93 Featured) -

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Fluidigm Corporation
• Illumina Inc.
• Oxford Gene Technology
• Oxford Nanopore Technologies
• Pacific Biosciences of California Inc.
• QIAGEN N.V.
• RainDance Technologies Inc.
• Roche Sequencing
• Thermo Fischer Scientific Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.